A. Villanueva, Cheryl E. Flores-Riva, Josephine R. Valdez
{"title":"Treatment of Hypertension in the Different Stages of Chronic Kidney Disease","authors":"A. Villanueva, Cheryl E. Flores-Riva, Josephine R. Valdez","doi":"10.15713/ins.johtn.0158","DOIUrl":null,"url":null,"abstract":"Hypertension (HTN) is the chronic elevation of blood pressure (BP) sufficient to increase the risk of HTN-mediated organ damage and other related complications in the general population, particularly in the presence of comorbidities.[1-4] It is the level of BP at which the benefits of lifestyle interventions or medical therapy outweigh the risks of treatment.[5] In 2015, the global prevalence of hypertension (HTN) was estimated to be 1.13 billion.[6] There is around 30–45% of adults worldwide diagnosed with HTN. Majority of those diagnosed with elevated BP are males. This is consistent across different countries regardless of socioeconomic status.[7] The aging population, sedentary lifestyles, and obesity contribute to the rise of HTN cases globally, with an estimated increase in disease prevalence to close to 1.5 billion by 2025.[8]","PeriodicalId":38918,"journal":{"name":"Open Hypertension Journal","volume":"12 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Hypertension Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15713/ins.johtn.0158","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Hypertension (HTN) is the chronic elevation of blood pressure (BP) sufficient to increase the risk of HTN-mediated organ damage and other related complications in the general population, particularly in the presence of comorbidities.[1-4] It is the level of BP at which the benefits of lifestyle interventions or medical therapy outweigh the risks of treatment.[5] In 2015, the global prevalence of hypertension (HTN) was estimated to be 1.13 billion.[6] There is around 30–45% of adults worldwide diagnosed with HTN. Majority of those diagnosed with elevated BP are males. This is consistent across different countries regardless of socioeconomic status.[7] The aging population, sedentary lifestyles, and obesity contribute to the rise of HTN cases globally, with an estimated increase in disease prevalence to close to 1.5 billion by 2025.[8]